European Congress of NeuroRehabilitation 2017

25–28 October 2017 • Lausanne, Switzerland

Congress details


(Gold Sponsorship)

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma.  Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

BOTOX® (100 Allergan Units Botulinum Toxin A) has been one of the key Allergan products for a long time. It is the only botulinum toxin type A in Switzerland with 8 approved indications in the field of neurological disorders, bladder function disorders and skin disorders. BOTOX® has been available on the Swiss market since 1994 and therefore, more than 20 years of experience has been gained with the product regarding safety, quality and efficacy. 

The indications in Switzerland (date of approval Switzerland):

1) Blepharospasm (1994)
2) Hemifacial spasm (1994)
3) Cervical dystonia (Torticollis spasmodicus) (1997)
4) Juvenile cerebral palsy (1998)
5) Post-stroke spasticity (1999)
6) Primary hyperhidrosis axillaris (2003)
7) Neurogenic detrusor overactivity (2012)
8) Overactive bladder (2013)

For further product information, please refer to

Frankfurt a. Main/DE
(Bronze Sponsorship)

With approximately 3,000 employees and 34 subsidiaries, Merz is a leading global provider in the fields of Neurotoxins and Aesthetics. Privately held for more than 100 years, the company is distinguished by its in-house research and development, solid financial strength and continuous growth. In addition to its unique portfolio of products for minimally invasive and non-invasive skin rejuvenation and tightening, Merz also develops neurotoxin therapy to treat neurologically induced movement disorders. OTC medicines, dietary supplements and skincare products round off the offerings from the company, which is headquartered in Frankfurt, Germany. In fiscal year 2015/16, the Merz Pharma Group generated revenue of EUR 1,092.9 million. More information is available at

(Bronze Sponsorship)

Further sponsors